Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - Wiley Online Library
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - europepmc.org
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
[PDF][PDF] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto, T Takahashi… - 2020 - academia.edu
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto, T Takahashi… - Cancer Science, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> In a subgroup of Japanese patients in the
ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and …
ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and …
Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - search.proquest.com
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
[HTML][HTML] Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - ncbi.nlm.nih.gov
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer
M Nishio, T Kato, S Niho, N Yamamoto… - Cancer …, 2020 - search.proquest.com
In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we
evaluated the efficacy and safety and determined the effects of dose modifications on …
evaluated the efficacy and safety and determined the effects of dose modifications on …